Free Trial

Stevanato Group (NYSE:STVN) Releases FY 2025 Earnings Guidance

Stevanato Group logo with Medical background

Stevanato Group (NYSE:STVN - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.530-0.570 for the period, compared to the consensus earnings per share estimate of 0.580. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Stephens raised Stevanato Group to a "strong-buy" rating in a report on Monday, April 21st. UBS Group decreased their price target on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a report on Friday, March 7th. Finally, William Blair reissued an "outperform" rating on shares of Stevanato Group in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of €25.70 ($28.88).

Get Our Latest Stock Report on STVN

Stevanato Group Price Performance

Shares of Stevanato Group stock traded down €0.36 ($0.40) during trading on Monday, reaching €23.64 ($26.56). 322,519 shares of the stock traded hands, compared to its average volume of 350,714. The company has a market capitalization of $7.16 billion, a price-to-earnings ratio of 50.30, a P/E/G ratio of 7.18 and a beta of 0.51. The business has a fifty day simple moving average of €21.12 and a two-hundred day simple moving average of €21.00. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group has a 52-week low of €16.56 ($18.61) and a 52-week high of €24.90 ($27.98).

Stevanato Group (NYSE:STVN - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, hitting the consensus estimate of €0.20 ($0.22). The company had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Sell-side analysts expect that Stevanato Group will post 0.5 EPS for the current year.

Stevanato Group Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be given a $0.0613 dividend. The ex-dividend date of this dividend is Thursday, June 5th. This represents a yield of 0.3%. This is a positive change from Stevanato Group's previous annual dividend of $0.05. Stevanato Group's dividend payout ratio (DPR) is currently 11.76%.

Stevanato Group Company Profile

(Get Free Report)

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.

See Also

Earnings History and Estimates for Stevanato Group (NYSE:STVN)

Should You Invest $1,000 in Stevanato Group Right Now?

Before you consider Stevanato Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.

While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Insider Stock Buys in April—Are They Still Good in May?
5 Blowout Earnings Winners That Could Soar Even Higher
5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines